JP2022530089A5 - - Google Patents

Info

Publication number
JP2022530089A5
JP2022530089A5 JP2021563185A JP2021563185A JP2022530089A5 JP 2022530089 A5 JP2022530089 A5 JP 2022530089A5 JP 2021563185 A JP2021563185 A JP 2021563185A JP 2021563185 A JP2021563185 A JP 2021563185A JP 2022530089 A5 JP2022530089 A5 JP 2022530089A5
Authority
JP
Japan
Application number
JP2021563185A
Other languages
Japanese (ja)
Other versions
JPWO2020219959A5 (https=
JP7650819B2 (ja
JP2022530089A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029929 external-priority patent/WO2020219959A1/en
Publication of JP2022530089A publication Critical patent/JP2022530089A/ja
Publication of JPWO2020219959A5 publication Critical patent/JPWO2020219959A5/ja
Publication of JP2022530089A5 publication Critical patent/JP2022530089A5/ja
Application granted granted Critical
Publication of JP7650819B2 publication Critical patent/JP7650819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563185A 2019-04-24 2020-04-24 抗-cd45抗体薬物コンジュゲート及びその使用 Active JP7650819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838280P 2019-04-24 2019-04-24
US62/838,280 2019-04-24
PCT/US2020/029929 WO2020219959A1 (en) 2019-04-24 2020-04-24 Anti-cd45 antibody drug conjugates and uses thereof

Publications (4)

Publication Number Publication Date
JP2022530089A JP2022530089A (ja) 2022-06-27
JPWO2020219959A5 JPWO2020219959A5 (https=) 2023-05-08
JP2022530089A5 true JP2022530089A5 (https=) 2023-05-08
JP7650819B2 JP7650819B2 (ja) 2025-03-25

Family

ID=72940686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563185A Active JP7650819B2 (ja) 2019-04-24 2020-04-24 抗-cd45抗体薬物コンジュゲート及びその使用

Country Status (4)

Country Link
US (1) US20220175951A1 (https=)
EP (1) EP3958910A4 (https=)
JP (1) JP7650819B2 (https=)
WO (1) WO2020219959A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
US9851359B2 (en) 2016-04-06 2017-12-26 Sony Corporation Of America Ultra bright dimeric or polymeric dyes with spacing linker groups
KR102526802B1 (ko) 2016-05-11 2023-05-02 소니그룹주식회사 초고명도 이량체성 또는 중합체성 염료
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
JP7551056B2 (ja) 2017-10-05 2024-09-17 ソニーグループ株式会社 プログラマブルなポリマー薬物
CN111093711A (zh) 2017-10-05 2020-05-01 索尼公司 可编程的树枝状药物
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
CN111565756A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的具有刚性间隔基团的聚合物
US12194104B2 (en) 2018-01-12 2025-01-14 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
EP3737419B1 (en) 2018-01-12 2024-04-10 Sony Group Corporation Phosphoalkyl polymers comprising biologically active compounds
US11874280B2 (en) 2018-03-19 2024-01-16 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
US12006438B2 (en) 2018-06-27 2024-06-11 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
EP3820944A1 (en) 2018-07-13 2021-05-19 Sony Corporation Polymeric dyes having a backbone comprising organophosphate units
JP2022512781A (ja) * 2018-10-30 2022-02-07 マジェンタ セラピューティクス インコーポレイテッド 同種造血幹細胞移植の方法
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
WO2022125564A1 (en) 2020-12-07 2022-06-16 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
EP4408477A1 (en) * 2021-09-30 2024-08-07 Sony Group Corporation Pyrrolobenzodiazepine conjugates for cancer treatment
WO2023183927A2 (en) 2022-03-24 2023-09-28 Actinium Pharmaceuticals, Inc. Humanized anti-cd45 antibodies
JP2026500540A (ja) 2022-12-23 2026-01-07 シメイオ セラピューティクス アーゲー Cd45を標的とする抗体
CN120554513B (zh) * 2025-07-28 2025-11-21 杭州华大生命科学研究院 一种抗cd45抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190658A1 (es) * 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
HUE071169T2 (hu) * 2016-03-07 2025-08-28 Actinium Pharmaceuticals Inc Stabilizált, radioaktívan jelölt anti-CD45 immunglobulin-készítmények
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
CA3117367A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Anti-cd45 antibodies and conjugates thereof

Similar Documents

Publication Publication Date Title
JP2022530089A5 (https=)
JP2023514347A5 (https=)
BR102021018926A2 (https=)
CN305530619S (https=)
CN305760122S (https=)
CN305777836S (https=)
CN305777824S (https=)
CN305776527S (https=)
CN305776258S (https=)
CN305776069S (https=)
CN305688526S (https=)
CN305761148S (https=)
CN305760456S (https=)
CN305537093S (https=)
CN305536180S (https=)
CN305529612S (https=)
CN305688043S (https=)
CN305758737S (https=)
CN305536099S (https=)
CN305756229S (https=)
CN305753984S (https=)
CN305534548S (https=)
CN305532547S (https=)
CN305531561S (https=)
CN306420063S (https=)